Sartorius Stedim Biotech S.A
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more
Sartorius Stedim Biotech S.A (SDMHF) - Total Assets
Latest total assets as of December 2025: $8.01 Billion USD
Based on the latest financial reports, Sartorius Stedim Biotech S.A (SDMHF) holds total assets worth $8.01 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sartorius Stedim Biotech S.A - Total Assets Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech S.A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sartorius Stedim Biotech S.A - Asset Composition Analysis
Current Asset Composition (December 2025)
Sartorius Stedim Biotech S.A's total assets of $8.01 Billion consist of 18.0% current assets and 82.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.3% |
| Accounts Receivable | $227.21 Million | 2.8% |
| Inventory | $690.64 Million | 8.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.54 Billion | 19.2% |
| Goodwill | $2.88 Billion | 36.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sartorius Stedim Biotech S.A's current assets represent 18.0% of total assets in 2025, a decrease from 53.2% in 2005.
- Cash Position: Cash and equivalents constituted 5.3% of total assets in 2025, up from 2.7% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 54.0% of total assets, an increase from 8.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 36.0% of total assets.
Sartorius Stedim Biotech S.A Competitors by Total Assets
Key competitors of Sartorius Stedim Biotech S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Sartorius Stedim Biotech S.A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sartorius Stedim Biotech S.A generates 0.37x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Sartorius Stedim Biotech S.A generates $ 3.31 in net profit.
Sartorius Stedim Biotech S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 1.85 | 1.50 |
| Quick Ratio | 0.53 | 1.12 | 0.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $29.09 Million | $ 802.20 Million | $ 353.80 Million |
Sartorius Stedim Biotech S.A - Advanced Valuation Insights
This section examines the relationship between Sartorius Stedim Biotech S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.95 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | $8.01 Billion |
| Market Capitalization | $5.66 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sartorius Stedim Biotech S.A's assets below their book value (0.71 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Sartorius Stedim Biotech S.A's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sartorius Stedim Biotech S.A (2005–2025)
The table below shows the annual total assets of Sartorius Stedim Biotech S.A from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.01 Billion | -2.93% |
| 2024-12-31 | $8.26 Billion | +6.67% |
| 2023-12-31 | $7.74 Billion | +52.80% |
| 2022-12-31 | $5.07 Billion | +28.20% |
| 2021-12-31 | $3.95 Billion | +28.73% |
| 2020-12-31 | $3.07 Billion | +68.61% |
| 2019-12-31 | $1.82 Billion | +15.84% |
| 2018-12-31 | $1.57 Billion | +11.93% |
| 2017-12-31 | $1.40 Billion | +17.40% |
| 2016-12-31 | $1.20 Billion | +12.17% |
| 2015-12-31 | $1.07 Billion | +17.58% |
| 2014-12-31 | $906.76 Million | +4.08% |
| 2013-12-31 | $871.23 Million | +9.74% |
| 2012-12-31 | $793.87 Million | +10.16% |
| 2011-12-31 | $720.66 Million | +9.80% |
| 2010-12-31 | $656.34 Million | -1.73% |
| 2009-12-31 | $667.86 Million | +2.38% |
| 2008-12-31 | $652.34 Million | +1.81% |
| 2007-12-31 | $640.72 Million | +69.80% |
| 2006-12-31 | $377.34 Million | +4.09% |
| 2005-12-31 | $362.53 Million | -- |